The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
A Daei Sorkhabi, L Mohamed Khosroshahi… - Frontiers in …, 2023 - frontiersin.org
The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …
hematologic cancers have increased the previously unprecedented excitement to use this …
CAR T-cell therapy: a new era in cancer immunotherapy
AN Miliotou, LC Papadopoulou - Current pharmaceutical …, 2018 - ingentaconnect.com
Background: Cancer is one of the leading causes of death worldwide. Over the years, a
number of conventional cytotoxic approaches for neoplastic diseases has been developed …
number of conventional cytotoxic approaches for neoplastic diseases has been developed …
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
Opening doors with ultrasound and microbubbles: Beating biological barriers to promote drug delivery
Apart from its clinical use in imaging, ultrasound has been thoroughly investigated as a tool
to enhance drug delivery in a wide variety of applications. Therapeutic ultrasound, as such …
to enhance drug delivery in a wide variety of applications. Therapeutic ultrasound, as such …
Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities
BACKGROUND Chimeric antigen receptor (CAR) T cell immunotherapy has resulted in
complete remission (CR) and durable response in highly refractory patients. However …
complete remission (CR) and durable response in highly refractory patients. However …
[HTML][HTML] Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle
The immune system is involved in the initiation and progression of cancer. Research on
cancer and immunity has contributed to the development of several clinically successful …
cancer and immunity has contributed to the development of several clinically successful …
Dendritic cell therapy in cancer treatment; the state-of-the-art
M Sadeghzadeh, S Bornehdeli… - Life sciences, 2020 - Elsevier
Dendritic cells (DCs) are considered as professional antigen presenting cells (APCs),
containing a variety of subsets, that can be resident in organs or migrating among the …
containing a variety of subsets, that can be resident in organs or migrating among the …
Selenium nanoparticles regulates selenoprotein to boost cytokine-induced killer cells-based cancer immunotherapy
As one of the typical adoptive cell transfer modality, cytokine-induced killer cell (CIK)-
mediated immunotherapy exhibits promising applications in cancer treatment. However, the …
mediated immunotherapy exhibits promising applications in cancer treatment. However, the …
Clinical development of CAR T cell therapy in China: 2020 update
J Wei, Y Guo, Y Wang, Z Wu, J Bo, B Zhang… - Cellular & molecular …, 2021 - nature.com
Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in the
treatment of hematological malignancies. In recent years, fast-growing CAR T clinical trials …
treatment of hematological malignancies. In recent years, fast-growing CAR T clinical trials …
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells
MR Verneris, M Karami, J Baker, A Jayaswal… - Blood, 2004 - ashpublications.org
Activating and expanding T cells using T-cell receptor (TCR) cross-linking antibodies and
interleukin 2 (IL-2) results in potent cytotoxic effector cells capable of recognizing a broad …
interleukin 2 (IL-2) results in potent cytotoxic effector cells capable of recognizing a broad …